Clinical Research Directory
Browse clinical research sites, groups, and studies.
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Sponsor: Grit Biotechnology
Summary
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
Official title: A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-14
Completion Date
2028-01-13
Last Updated
2025-09-15
Healthy Volunteers
No
Conditions
Interventions
GT719 Injection
GT719 Injection
Locations (1)
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China